Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is deemed one of the most promising mid-cap healthcare stocks under $50, with Wells Fargo analyst Eva Fortea Verdejo assigning a Buy rating and a price target of $45, anticipating a 15.77% increase. Updates on the Phase 2 clinical study on KPL-387 monotherapy aim to transition patients with recurrent pericarditis to the drug. Successful outcomes could boost pipeline value and investor interest, with all 6 analysts giving Buy ratings and a consensus price target of $52.83, representing a 22.3% upside potential. Kiniksa Pharmaceuticals International focuses on developing therapeutic medicines for chronic debilitating diseases, particularly cardiovascular conditions, at the clinical stage.

Read more at Yahoo Finance: Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)